Online citations, reference lists, and bibliographies.
← Back to Search

Clinical Utility Of HIV-1 Genotyping And Expert Advice: The Havana Trial

C. Tural, L. Ruiz, C. Holtzer, J. Schapiro, P. Viciana, Juan R. González, P. Domingo, C. Boucher, C. Rey-Joly, B. Clotet
Published 2002 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy Visualize in Litmaps
Share
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Get Citationsy
Objective To determine whether HIV-1 genotyping and expert advice add additional short-term virologic benefit in guiding antiretroviral changes in HIV+ drug-experienced patients. Design A two factorial (genotyping and expert advice), randomized, open label, multi-center trial. The patients were stratified according to the number of treatment failures. Patients and methods HIV-1 infected patients on stable antiretroviral therapy who presented virological failure were included into the study. Genotypic testing was performed by using TrueGene HIV Genotyping kit and the results were interpreted by a software package (RetroGram®, version 1.0). An expert advisory committee suggested the new therapeutic approach based on clinical information alone or on clinical information plus HIV-1 genotyping results. Plasma HIV-1 RNA load, CD4+ cell count and adverse events were recorded at baseline and every 12 weeks. Results A total of 326 patients were included. The baseline CD4+ cell count and plasma HIV-1 RNA were 387 (± 224) × 106 cells/l and 4 (± 1) log10 respectively. The proportion of patients with plasma HIV-1 RNA < 400 copies/ml at 24 weeks differed between genotyping and no genotyping arms (48.5 and 36.2%, P < 0.05). Factors associated with a higher probability of plasma HIV-1 RNA < 400 copies/ml were HIV-1 genotyping [odds ratio (OR), 1.7; 95% confidence interval (CI), 1.1–2.8;P = 0.016] and the expert advice in patients failing to a second-line antiretroviral therapy (OR, 3.2; 95% CI, 1.2–8.3;P = 0.016). Conclusions HIV-1 genotyping interpreted by a software package improves the virological outcome when it is added to the clinical information as a basis for decisions on changing antiretroviral therapy. The expert advice also showed virologic benefit in the second failure group.
This paper references
10.1126/SCIENCE.2479983
Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT).
B. Larder (1989)
10.1126/SCIENCE.2467383
HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy.
B. Larder (1989)
Effect of stage of disease and drug dose on zidovudine susceptibilities of isolates of human immunodeficiency virus.
D. Richman (1990)
10.1038/374569A0
In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors
J. Condra (1995)
10.1093/INFDIS/171.5.1166
Evaluation of safety and efficacy of 3TC (lamivudine) in patients with asymptomatic or mildly symptomatic human immunodeficiency virus infection: a phase I/II study.
R. van Leeuwen (1995)
Evaluation of safety and ef®cacy of 3TC (lamivudine) in patients with asymptomatic or mildly symptomatic human immunode®ciency virus infection: a phase I/II study
R van Leeuwen (1995)
10.1056/NEJM199603143341106
Physicians' experience with the acquired immunodeficiency syndrome as a factor in patients' survival.
M. Kitahata (1996)
10.1097/00002030-199610090-00007
Drug resistance and virologic response in NUCA 3001, a randomized trial of lamivudine (3TC) versus zidovudine (ZDV) versus ZDV plus 3TC in previously untreated patients
D. Kuritzkes (1996)
10.1038/nm0796-760
Ordered accumulation of mutations in HIV protease confers resistance to ritonavir
A. Molla (1996)
10.1097/00002030-199612005-00005
Clinical significance of drug resistance in HIV‐1 infection
D. Kuritzkes (1996)
Clinical signi®cance of drug resistance in HIV-1 infection
DR Kuritzkes (1996)
10.1038/NM0397-268
HIV-1: Gambling on the evolution of drug resistance?
A. J. Brown (1997)
10.7326/0003-4819-128-11-199806010-00017
Resisting Resistance: Maximizing the Durability of Antiretroviral Therapy
J. Condra (1998)
10.1001/JAMA.279.24.2000
Drug-resistant HIV-1: the virus strikes back.
D. Mayers (1998)
10.1097/00002030-199804000-00011
The relationship of clinic experience with advanced HIV and survival of women with AIDS
C. Laine (1998)
10.1016/S0140-6736(99)00128-2
Time to genotype for selection of antiretro viral regimens in pre viously treated patients?
J. Falloon (1999)
10.1016/S0140-6736(05)76910-5
Drug-resistant genotyping in HIV-1 therapy
B. Zöllner (1999)
10.7326/0003-4819-131-11-199912070-00003
HIV-1 Genotypic Resistance Patterns Predict Response to saquinavirritonavir Therapy in Patients in Whom Previous Protease Inhibitor Therapy Had Failed
A. Zolopa (1999)
10.1086/515081
Clinical experience and choice of drug therapy for human immunodeficiency virus disease.
C. Brosgart (1999)
10.1097/00002030-199902040-00001
Impact of drug resistance mutations on virologic response to salvage therapy. Swiss HIV Cohort Study.
P. Lorenzi (1999)
10.1016/S0140-6736(98)12291-2
Drug-resistance genotyping in HIV-1 therapy: the VIRAD APT randomi sed controlled trial
J. Durant (1999)
Clinical experience and choice of drug therapy for human immunode®ciency virus disease
CL Brosgart (1999)
10.1001/JAMA.283.10.1329
Strategies for long-term success in the treatment of HIV infection.
J. Gallant (2000)
10.1001/JAMA.283.18.2417
Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel.
M. Hirsch (2000)
10.1001/JAMA.283.18.2442
HIV genotype and phenotype--arresting resistance?
C. Flexner (2000)
10.1001/JAMA.284.13.1647
The role of genotypic resistance testing in selecting therapy for HIV.
J. Pérez-Molina (2000)
10.1097/00002030-200006160-00001
A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy
J. Baxter (2000)
10.1177/135965350000500102
Persisting Long-Term Benefit of Genotype-Guided Treatment for HIV-Infected Patients Failing Haart. The Viradapt Study: Week 48 Follow-Up
P. Clevenbergh (2000)
10.1097/00002030-200005260-00013
Prevalence of genotypic and phenotypic resistance to anti-retroviral drugs in a cohort of therapy-naïve HIV-1 infected US military personnel
S. Wegner (2000)
10.1177/135965350000500113
HIV Drug Susceptibility and Treatment Response to Mega-Haart Regimen in Patients from the Frankfurt HIV Cohort
Veronica Miller (2000)
10.1001/jama.284.13.1647
The role of genotypic resistance testing in selecting therapy for HIV
Hirsch (2000)
10.1001/JAMA.283.3.381
Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel.
C. Carpenter (2000)
Quantitative prediction of HIV1 phenotypic drug resistance from genotypes: the virtual phenotype
BA Larder (2000)
Impact of treatment guided by phenotypic or genotypic resistance test on the response to antiretroviral therapy: a randomized trial (NARVAL, ANRS 088)
JL Meynard (2000)
Hospital Vall d'Hebron (Barcelona): (I. Ruiz
C Tural



This paper is referenced by
10.1038/s41436-020-01045-1
Effect of genetics clinical decision support tools on health-care providers' decision making: a mixed-methods systematic review.
Agnes Sebastian (2021)
10.1007/978-3-030-20491-4
Sexually Transmitted Infections in Adolescence and Young Adulthood: A Practical Guide for Clinicians
S. Hussen (2020)
Recognizing and Managing Antiretroviral Treatment Failure
(2020)
Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV
(2020)
10.1007/978-3-030-20491-4_17
Human Immunodeficiency Virus
Nikhil Ranadive (2020)
10.1136/bmjhci-2020-100141
OpenClinical.net: Artificial intelligence and knowledge engineering at the point of care
J. Fox (2020)
10.21105/JOSS.01186
sierra-local: A lightweight standalone application for drug resistance prediction
Jasper C Ho (2019)
10.1016/J.IDC.2019.05.004
Management of Virologic Failure and HIV Drug Resistance
S. Mccluskey (2019)
Genotypic and Phenotypic Resistance Assays
(2019)
10.1007/978-3-319-96830-8
Genomic Applications in Pathology
G. Netto (2019)
Dynamics of drug-resistant minor viral populations and phenotypic drug susceptibility in diverse HIV-1 subtypes
Ganeshappa Aralaguppe (2019)
HIV Genotype and Phenotype Testing
(2019)
10.1002/14651858.CD006495.pub5
Antiretroviral resistance testing in HIV‐positive people
T. Aves (2018)
10.3390/molecules23040956
HIV Resistance Prediction to Reverse Transcriptase Inhibitors: Focus on Open Data
O. Tarasova (2018)
4 Point Mutations and Antiviral Drug Resistance
J. Arellano‐Galindo (2018)
10.1101/393207
sierra-local: A lightweight standalone application for secure HIV-1 drug resistance prediction
Jasper C Ho (2018)
10.1007/978-3-319-95111-9_18
Laboratory Diagnosis of HIV-1 Infections: State of the Art
N. L. Nguyen (2018)
10.1080/15284336.2017.1349028
The REVAMP trial to evaluate HIV resistance testing in sub-Saharan Africa: a case study in clinical trial design in resource limited settings to optimize effectiveness and cost effectiveness estimates
M. Siedner (2017)
10.1101/117705
Comprehensive mapping of HIV-1 escape from a broadly neutralizing antibody
A. Dingens (2017)
Evolução clínica e laboratorial das crianças e adolescentes com HIV/AIDS após falha terapêutica orientada pela genotipagem
G. Fernandes (2017)
10.1016/j.jbi.2017.02.008
Cognitive systems at the point of care: The CREDO program
J. Fox (2017)
10.1016/j.chom.2017.05.003
Comprehensive Mapping of HIV-1 Escape from a Broadly Neutralizing Antibody.
A. Dingens (2017)
Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV
(2017)
Risk Factors of Clinical and Immunological Failure in South Indian Cohort on Generic Antiretroviral Therapy.
Mucheli Shravan Sadashiv (2017)
10.1002/14651858.CD006495.PUB4
Antiretroviral resistance testing in people living with HIV
J. Tambe (2017)
10.1016/j.virusres.2016.12.008
Promises and pitfalls of Illumina sequencing for HIV resistance genotyping.
C. Brumme (2017)
Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV
(2017)
10.1007/978-3-319-47266-9_38
Genotypic Assays for Monitoring Drug Resistance in HIV-1 Infection and for Other Chronic Viral Diseases
Ying-Shan Han (2017)
Proposal HIV Drug-Resistant Patient Information Management , Analysis , and Interpretation
Y. Singh (2017)
10.1016/S1473-3099(16)30118-9
Affordable HIV drug-resistance testing for monitoring of antiretroviral therapy in sub-Saharan Africa.
S. Inzaule (2016)
10.1016/S2352-3018(16)00046-1
Near real-time monitoring of HIV transmission hotspots from routine HIV genotyping: an implementation case study
A. Poon (2016)
10.17352/2455-3786.000018
Laboratory Algorithm in HIV Infection Diagnosis
Uğur Tüzüner (2016)
See more
Semantic Scholar Logo Some data provided by SemanticScholar